The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).
 
Ozge Gumusay
No Relationships to Disclose
 
Jonathan R. Renslo
No Relationships to Disclose
 
Chiara A. Wabl
No Relationships to Disclose
 
Amy Jo Chien
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Genentech (Inst); Lilly (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Melanie Catherine Majure
No Relationships to Disclose
 
Siti D. Rahmaputri
No Relationships to Disclose
 
Mark Moasser
No Relationships to Disclose
 
John Park
Stock and Other Ownership Interests - Merrimack
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech; Pfizer
Patents, Royalties, Other Intellectual Property - University of California- San Francisco
Expert Testimony - Genentech
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology